ACLU Challenges Patents on Breast Cancer Genes

Publication
Article
OncologyONCOLOGY Vol 23 No 7
Volume 23
Issue 7

The American Civil Liberties Union and the Public Patent Foundation at Benjamin N. Cardozo School of Law filed a lawsuit charging that patents on two human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit women’s options regarding their medical care.

The American Civil Liberties Union and the Public Patent Foundation at Benjamin N. Cardozo School of Law filed a lawsuit charging that patents on two human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit women's options regarding their medical care. Mutations along the BRCA1 and BRCA2 genes are responsible for most cases of hereditary breast and ovarian cancers. The lawsuit argues that the patents on these genes are unconstitutional and invalid.

Articles in this issue
What Is the Optimal Initial Treatment of Low-Risk Papillary Thyroid Cancer (and Why Is It Controversial)?
What Is the Optimal Initial Treatment of Low-Risk Papillary Thyroid Cancer (and Why Is It Controversial)?
Low-Risk Papillary Thyroid Cancer: Treatment Options and Patient Perceptions
Can Risk-Adapted Treatment Recommendations Replace the ‘One Size Fits All’ Approach for Early-Stage Thyroid Cancer Patients?
Prophylactic Central Lymph Node Dissection: Continued Controversy
Music Therapy
Music Therapy
LHRH Antagonists vs LHRH Agonists: Which Is More Beneficial in Prostate Cancer Therapy?
Is There a Role for LHRH Antagonists in Prostate Cancer?
Important Considerations in LHRH Antagonist Therapy for Prostate Cancer
The Role of LHRH Antagonists in the Treatment of Prostate Cancer
Maintenance Therapy With Pemetrexed Improves Overall Survival in Advanced NSCLC
PARP Inhibitors Show Promise for Hard-to-Treat Breast Cancers
Therapeutic Cancer Vaccine Significantly Prolongs Disease-Free Survival for Follicular Lymphoma
Vaccine Improves Response Rate and Extends Progression-Free Survival in Metastatic Melanoma
‘Natural’ Hormone Replacement and Breast Cancer Risk: Evidence for Safety and Efficacy
Phase IIIB Trial of Intermittent Degarelix Therapy Launched
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content
Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.

Pembrolizumab Maintenance Yields Enduring Responses in HER2– Breast Cancer

April 23rd 2024
Article

Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer

January 15th 2024
Podcast

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast Cancer Recurrence

7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast Cancer Recurrence

April 22nd 2024
Article

DCISionRT is a risk-assessment test for patients designed to predict RT benefit and develop their recurrence risk after surgery alone or with radiation.

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

January 8th 2024
Podcast

Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.

70 Navigating Lymphedema: The Impact of Indocyanine Green Lymphography (ICG_L) on Personalized Therapy Outcomes in Patients With Breast Cancer (BC)

70 Navigating Lymphedema: The Impact of Indocyanine Green Lymphography (ICG_L) on Personalized Therapy Outcomes in Patients With Breast Cancer (BC)

April 20th 2024
Article
The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer

April 19th 2024
Article

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.